
  
    
      
        Tumor_NNP Antigen_NNP Recognition_NNP by_IN Cytolytic_NNP T_NN Lymphocytes_NNP
        CD_NNP 8_CD
        +_NN cytolytic_JJ T_NN lymphocytes_NNS (_( CTLs_NNP )_) are_VBP the_DT primary_JJ effector_NN cells_NNS of_IN the_DT
        adaptive_JJ immune_JJ system_NN and_CC have_VBP a_DT major_JJ role_NN in_IN protecting_VBG us_PRP from_IN a_DT vast_JJ array_NN of_IN diseases_NNS
        including_VBG cancer_NN ._. CTLs_NNP specifically_RB recognize_VBP and_CC lyse_NN targets_NNS through_IN the_DT interaction_NN of_IN T_NN
        cell_NN receptors_NNS (_( TCRs_NNP )_) on_IN the_DT surface_NN of_IN the_DT T_NN lymphocyte_NN with_IN protein_NN fragments_NNS (_( peptides_NNS )_)
        presented_VBN on_IN the_DT surface_NN of_IN target_NN cells_NNS ,_, in_IN association_NN with_IN major_JJ histocompatibility_NN
        complex_JJ (_( MHC_NNP )_) class_NN I_PRP molecules_NNS ._. When_WRB a_DT particular_JJ CTL_NNP interacts_NNS with_IN a_DT target_NN cell_NN ,_, it_PRP
        rapidly_RB divides_VBZ to_TO form_VB a_DT clonal_NN population_NN of_IN T_NN cells_NNS with_IN the_DT identical_JJ TCR_NNP ._.
        Townsend_NNP and_CC colleagues_NNS first_JJ elucidated_JJ the_DT molecular_JJ basis_NN of_IN target_NN cell_NN recognition_NN
        by_IN CTLs_NNP in_IN 1985_CD [_NN 1_CD ]_NN ._. They_PRP showed_VBD that_IN antigens_NNS are_VBP processed_VBN inside_IN the_DT target_NN cell_NN into_IN
        nine-_NN or_CC ten-amino-acid-long_JJ peptides_NNS ,_, which_WDT are_VBP then_RB presented_VBN at_IN the_DT surface_NN in_IN
        association_NN with_IN MHC_NNP class_NN I_PRP molecules_NNS ._. This_DT discovery_NN suggested_VBD the_DT possibility_NN of_IN using_VBG
        short_JJ synthetic_JJ peptides_NNS mimicking_VBG naturally_RB processed_VBN antigens_NNS as_IN immunotherapeutic_JJ drugs_NNS
        and_CC vaccines_NNS ._. Short_JJ synthetic_JJ peptides_NNS are_VBP ideal_JJ for_IN drug_NN development_NN because_IN of_IN the_DT
        relatively_RB low_JJ cost_NN of_IN production_NN ,_, easy_JJ storage_NN ,_, and_CC high_JJ safety_NN ._. However_RB ,_, not_RB all_DT peptides_NNS
        and_CC MHC_NNP alleles_NNS work_VBP well_RB together_RB to_TO stimulate_VB CTLs_NNP ._. So_RB for_IN clinical_JJ use_NN ,_, either_CC patients_NNS
        would_MD have_VB to_TO be_VB selected_VBN for_IN treatment_NN based_VBN on_IN their_PRP$ MHC_NNP I_PRP type_NN or_CC it_PRP would_MD be_VB necessary_JJ
        to_TO make_VB multiple_JJ peptides_NNS to_TO cover_VB the_DT majority_NN of_IN MHC_NNP class_NN I_PRP alleles_NNS in_IN a_DT given_VBN
        population_NN ._.
        Furthermore_RB ,_, before_IN Boon_NNP and_CC colleagues_NNS cloned_VBN the_DT first_JJ antigen_NN recognized_VBN by_IN
        tumor-reactive_JJ CTLs_NNP in_IN 1991_CD [_NN 2_CD ]_NN ,_, it_PRP was_VBD not_RB clear_JJ which_WDT antigens_NNS were_VBD recognized_VBN by_IN
        tumor-reactive_JJ CTLs_NNP in_IN humans_NNS ;_: so_RB ,_, it_PRP was_VBD not_RB possible_JJ to_TO rationally_RB design_VB cancer_NN
        vaccines_NNS ._. Now_RB ,_, however_RB ,_, a_DT long_JJ list_NN of_IN more_JJR or_CC less_RBR tumor-specific_JJ antigens_NNS has_VBZ been_VBN
        generated_VBN [_NN 3_CD ]_NN ._. Most_JJS of_IN the_DT peptides_NNS identified_VBN so_RB far_RB are_VBP either_CC normal_JJ self_NN proteins_NNS
        aberrantly_RB expressed_VBD in_IN cancer_NN but_CC not_RB in_IN most_JJS other_JJ adult_NN normal_JJ tissues_NNS or_CC
        tissue-specific_JJ antigens_NNS also_RB expressed_VBD in_IN certain_JJ types_NNS of_IN cancer_NN ._. Some_DT patients_NNS show_VBP a_DT
        spontaneous_JJ CD_NNP 8_CD
        +_NN T_NN cell_NN response_NN (_( occasionally_RB at_IN high_JJ levels_NNS )_) that_WDT is_VBZ specific_JJ for_IN
        several_JJ of_IN these_DT antigens_NNS ._. The_DT development_NN of_IN such_JJ responses_NNS ,_, however_RB ,_, requires_VBZ a_DT large_JJ
        tumor_NN load_NN ,_, occurs_VBZ late_RB in_IN the_DT disease_NN ,_, and_CC probably_RB does_VBZ not_RB cause_VB the_DT efficient_JJ
        destruction_NN of_IN the_DT tumor_NN cells_NNS [_NN 4_CD ]_NN ._. Thus_RB ,_, a_DT central_JJ objective_NN in_IN cancer_NN immunotherapy_NN is_VBZ to_TO
        efficiently_RB produce_VB tumor-reactive_JJ CTLs_NNP at_IN an_DT earlier_JJR phase_NN of_IN the_DT disease_NN ._.
      
      
        Heteroclitic_NNP Tumor_NNP Antigen_NNP Peptides_NNP
        Unfortunately_RB ,_, some_DT synthetic_JJ peptides_NNS ,_, including_VBG some_DT corresponding_JJ to_TO immunodominant_NN
        epitopes_NNS (_( those_DT which_WDT cause_VBP the_DT biggest_JJS part_NN of_IN the_DT immune_JJ response_NN )_) from_IN tumor_NN antigens_NNS ,_,
        only_RB seem_VBP to_TO bind_NN MHC_NNP class_NN I_PRP molecules_NNS with_IN medium_NN to_TO low_JJ affinity_NN and_CC /_NN or_CC are_VBP recognized_VBN
        by_IN specific_JJ T_NN cells_NNS with_IN relatively_RB low_JJ avidity_NN ._. These_DT characteristics_NNS are_VBP the_DT likely_JJ cause_NN
        of_IN the_DT poor_JJ immune_JJ reaction_NN generated_VBN by_IN these_DT peptides_NNS [_NN 5_CD ]_NN ._. One_CD strategy_NN to_TO improve_VB the_DT
        immune_JJ reaction_NN is_VBZ to_TO make_VB what_WP are_VBP called_VBN heteroclitic_JJ antigen_NN variants_NNS ._. By_IN improving_VBG
        either_DT peptide_NN binding_JJ to_TO MHC_NNP ,_, recognition_NN by_IN TCRs_NNP ,_, or_CC both_DT ,_, these_DT variants_NNS have_VBP increased_VBN
        peptide_NN antigenicity_NN and_CC immunogenicity_NN ._.
        Solinger_NNP and_CC colleagues_NNS were_VBD the_DT first_JJ to_TO describe_VB antigen_NN variants_NNS producing_VBG T_NN cell_NN
        responses_NNS that_WDT were_VBD stronger_JJR than_IN those_DT elicited_JJ by_IN the_DT parental_JJ sequences_NNS [_NN 6_CD ]_NN ._. Some_DT
        heteroclitic_JJ tumor_NN antigen_NN peptides_NNS that_WDT showed_VBD highly_RB improved_VBN antigenicity_NN and_CC
        immunogenicity_NN in_IN preclinical_JJ studies_NNS ,_, and_CC which_WDT also_RB cross-reacted_JJ well_RB with_IN CTLs_NNP
        generated_VBD against_IN the_DT parental_JJ sequence_NN ,_, were_VBD tested_VBN in_IN clinical_JJ trials_NNS ._. The_DT peptides_NNS
        selected_VBN for_IN trials_NNS mostly_RB contained_VBD substitutions_NNS of_IN anchoring_VBG amino_JJ acids_NNS that_WDT were_VBD
        designed_VBN to_TO increase_VB peptide_NN binding_VBG to_TO the_DT MHC_NNP molecule_NN while_IN minimally_RB changing_VBG the_DT shape_NN
        of_IN the_DT epitope_NN [_NN 7_CD ,_, 8_CD ]_NN ._.
        In_IN a_DT study_NN by_IN Lee_NNP and_CC colleagues_NNS in_IN this_DT issue_NN of_IN 
        PLoS_NNP Medicine_NNP [_NN 9_CD ]_NN ,_, despite_IN the_DT careful_JJ study_NN design_NN ,_, vaccination_NN with_IN
        these_DT peptides_NNS resulted_VBD in_IN the_DT recruitment_NN of_IN T_NN cells_NNS that_WDT bound_VBN antigens_NNS less_RBR efficiently_RB
        and_CC had_VBD lower_JJR tumor_NN reactivity_NN than_IN those_DT from_IN the_DT endogenous_JJ response_NN to_TO the_DT tumor_NN ._. The_DT
        authors_NNS propose_VBP that_IN the_DT cause_NN for_IN the_DT decreased_VBN affinity_NN of_IN vaccine-elicited_JJ CTLs_NNP could_MD be_VB
        the_DT high_JJ antigen_NN density_NN of_IN these_DT synthetic_JJ peptides_NNS on_IN antigen-presenting_JJ cells_NNS ._. An_DT
        alternative_JJ explanation_NN ,_, however_RB ,_, is_VBZ that_IN the_DT synthetic_JJ peptides_NNS used_VBN for_IN vaccination_NN
        simply_RB fail_VB to_TO faithfully_RB mimic_VB the_DT naturally_RB processed_VBN antigens_NNS (_( Figure_NN 1_LS )_) ._. The_DT use_NN of_IN
        peptides_NNS that_WDT differ_VBP from_IN those_DT resulting_VBG from_IN natural_JJ intracellular_NN processing_NN has_VBZ
        previously_RB given_VBN rise_NN to_TO similar_JJ problems_NNS [_NN 10_CD ,_, 11_CD ]_NN ._. In_IN any_DT case_NN ,_, the_DT enormous_JJ diversity_NN in_IN
        the_DT normal_JJ TCR_NNP repertoire_NN provides_VBZ a_DT molecular_JJ explanation_NN of_IN the_DT observed_VBN phenomenon_NN ._.
        These_DT results_NNS emphasize_VBP how_WRB difficult_JJ it_PRP is_VBZ to_TO translate_VB findings_NNS ,_, such_JJ as_IN the_DT spectacular_JJ
        results_NNS obtained_VBN by_IN the_DT vaccination_NN of_IN TCR_NNP transgenic_JJ mice_NNS with_IN heteroclitic_JJ peptides_NNS [_NN 12_CD ]_NN ,_,
        into_IN an_DT application_NN for_IN normal_JJ animals_NNS and_CC humans_NNS ._.
      
      
        Conclusion_NNP
        It_PRP is_VBZ increasingly_RB clear_JJ that_IN even_RB the_DT smallest_JJS alteration_NN in_IN the_DT structure_NN of_IN the_DT MHC_NNP
        peptide_NN complex_JJ can_MD result_VB in_IN significant_JJ changes_NNS in_IN which_WDT TCRs_NNP are_VBP selected_VBN after_IN
        vaccination_NN ._. Thus_RB ,_, manipulating_VBG the_DT immune_JJ T_NN cell_NN repertoire_NN in_IN vivo_NN through_IN the_DT use_NN of_IN
        heteroclitic_JJ tumor_NN antigen_NN peptide_NN variants_NNS could_MD be_VB harder_RBR than_IN anticipated_VBN ._. As_IN the_DT field_NN
        moves_NNS rapidly_RB towards_IN the_DT use_NN of_IN new_JJ vaccine_NN adjuvants_NNS with_IN high_JJ immunogenic_JJ potential_JJ
        [_NN 13_CD ]_NN ,_, reassessment_NN of_IN the_DT immunogenicity_NN of_IN natural_JJ sequences_NNS could_MD be_VB worthwhile_JJ in_IN some_DT
        cases_NNS ._. In_IN addition_NN ,_, the_DT careful_JJ analysis_NN of_IN antigen-specific_JJ T_NN cell_NN clones_NNS ,_, such_JJ as_IN that_DT
        reported_VBD here_RB by_IN Lee_NNP and_CC colleagues_NNS ,_, will_MD be_VB crucial_JJ to_TO ascertain_VB the_DT quality_NN of_IN the_DT
        elicited_JJ immune_JJ response_NN ._.
      
    
  
